Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,143

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
HypercholesterolemiaMetabolic Syndrome
Interventions
DRUG

ezetimibe (+) simvastatin

Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.

DRUG

Comparator: atorvastatin calcium

"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."

DRUG

Comparator: Placebo (unspecified)

"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00409773 - Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED) | Biotech Hunter | Biotech Hunter